Australian doctors now have clearer, evidence-based guidance to help patients manage their weight and lower their risk of a heart attack or stroke.
The Heart Foundation has released the nation’s first Clinical Consensus Statement on obesity and cardiovascular disease (CVD).
Intended for healthcare professionals whose patients have heart disease or a high risk of developing it, it includes recommendations for new obesity medicines to reduce heart disease risk.
Around two thirds of adults in Australia are either overweight or obese, with more than half the adult population projected to be obese by 2035.
The Consensus Statement recommends managing obesity and CVD risk via four pillars; nutrition, physical activity, clarity on the use of weight loss drugs and around recommending weight loss surgery.
Heart Foundation chief medical advisor Professor Garry Jennings said new therapies had changed what was possible in obesity care and this statement shows how to use them safely and appropriately to improve heart health.
“This is a line in the sand moment for cardiovascular care in Australia: obesity must be addressed early, seriously and as part of lifelong heart health.”
The statement suggests Semaglutide (GLP-1 receptor agonist) be considered for weight loss in people with established CVD such as a history of heart attack, to reduce cardiovascular risk.
While a GLP-1 or GIP/GLP-1 receptor agonist with proven cardiovascular benefit (including semaglutide, liraglutide or tirzepatide) should be considered in adults with type 2 diabetes to reduce cardiovascular risk.
Where lifestyle changes and medicines have not led to weight loss related health improvements or for people with a high BMI, the statement advises metabolic bariatric surgery may be recommended.
A heart‑healthy eating pattern continues to be recommended, with reduced energy intake advised for weight loss.
RELATED: The rise of weight loss drugs and the potential pitfalls
Regular physical activity is encouraged, including moderate to vigorous aerobic activity and resistance training to improve heart and overall health.
The Consensus Statement also considers weight stigma, the unique needs of high-priority populations and the growing clinical significance of cardiovascular-kidney-metabolic syndrome.
A range of practical resources are available alongside the Clinical Consensus Statement on Obesity and Cardiovascular Disease on the Heart Foundation website.
Want more news, clinicals, features and guest columns delivered straight to you? Subscribe for free to WA’s only independent magazine for medical practitioners.
Want to submit an article? Email [email protected]